Clinical trial NCT05416866: Transversus Abdominis Plane Block Plus Quadratus Lumborum Block or Retrolaminar Block of Multiple Injections for Postoperative Analgesia Following Laparoscopic Colorectal Surgery
Official title: Transversus Abdominis Plane Block Plus Quadratus Lumborum Block or Retrolaminar Block of Multiple Injections for Postoperative Analgesia Following Laparoscopic Colorectal Surgery: A Randomized, Double-blind, Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Quadratus Lumborum Block
Analgesia
Laparoscopic
Colorectal
Lead sponsor: Gansu Provincial Hospital
Sponsor class: OTHER
First posted: 2022-06-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A randomized, double-blind, controlled trial
Primary purpose: TREATMENT

Brief summary: Our hypothesis was that transversus abdominis plane block plus retrolaminar block would reduce postoperative sufentanil consumption and provide superior analgesia compared with transversus abdominis plane block plus quadratus lumborum block for laparoscopic colorectal surgery.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I-II class
* Colorectal cancer patients
* 18 and 80 years old
* Elective laparoscopic colorectal surgery

Exclusion Criteria:

* serious complications associated with other systems:
* severe cardiac insufficiency
* renal failure
* hepatic encephalopathy
* infection in the block injection area
* coagulopathy
* a known allergy to local anesthetics
* a previous history of tranquilizer or opioid abuse,
* body mass index (BMI) greater than 30 kg/m2 or less than 18 kg/m2,
* inability to cooperate with the assessment of visual analogue scale (VAS) pain scores
* refusal to participate in the study

Primary outcomes:
measure: the cumulative consumption of sufentanil
timeFrame: 24 hours after nerves block
Secondary outcomes:
measure: the patient's mean arterial pressure (MAP), HR at rest and during movement at 1, 2, 4, 6, 8, 12, 18, 24 after nerves block
timeFrame: the time for completion of nerves block was time 0
measure: cumulative sufentanil consumption at predetermined time intervals
timeFrame: within 24 hour after nerves block
measure: time until the earliest single patient-controlled analgesia (PCA) dose of sufentanil
timeFrame: within 24 hour after nerves block
measure: the number of PCA press
timeFrame: within 24 hour after nerves block
measure: time until the earliest rescue analgesia and antiemetic
timeFrame: within 24 hour after nerves block
measure: the total dose of rescue analgesia and antiemetic
timeFrame: within 24 hour after nerves block
measure: block-related complications
timeFrame: within 24 hour after nerves block
measure: other side events
timeFrame: within 24 hour after nerves block
measure: patient satisfaction with pain management
timeFrame: at 24th hour after nerves block
measure: the length of hospital stay
timeFrame: up to 2 weeks
measure: Visual Analog Score (VAS) for pain at rest and during movement at 1, 2, 4, 6, 8, 12, 18, 24 after nerves block
timeFrame: the time for completion of nerves block was time 0
Other outcomes:
Locations:
Study officials:
References: